Cyllene Therapeutics Presents Interim Data from Phase 1b/2a Clinical Trial Showing EG110A Reduced Urinary Episodes in Patients with SCI at the International Continence Society conference
October 07, 2026- Clinically relevant reduction in urinary incontinence episodes consistently maintained overtime including in the initial set of patients reaching end of study at 52 weeks
- Treatment was well tolerated, with no serious drug related side effects or dose-limiting toxicity
Read the full Press Release here